Table 3.
Cytokine and 8-isoprostane concentrations in plasma and urine pre- and post-HME vs no-HME trials
| HME | No HME | ||||||
|---|---|---|---|---|---|---|---|
| Pre | Post | p value* | Pre | Post | p value* | p value† | |
| Plasma- IL-5, pg ml−1 | 0.46 (0.35–0.61) | 0.45 (0.29–0.72) | 0.179 | 0.42 (0.27–0.59) | 0.41 (0.32–0.47) | 0.235 | 0.377 |
| Plasma- IL-6, pg ml−1 | 0.53 (0.34–1.18) | 1.10 (0.58–1.43) | < 0.001 | 0.44 (0.37–0.98) | 0.95 (0.63–1.62) | < 0.001 | 0.823 |
| Plasma- IL-8, pg ml−1 | 2.58 (2.09–3.33) | 3.19 (2.54–4.10) | < 0.001 | 2.61 (2.13–2.94) | 3.33 (2.60–4.08) | < 0.001 | 0.286 |
| Plasma- IL-10, pg ml−1 | 0.33 (0.23–0.43) | 0.35 (0.22–0.84) | 0.006 | 0.33 (0.22–0.62) | 0.38 (0.27–0.73) | 0.008 | 0.142 |
| Plasma- TNF-alpha, pg ml−1 | 1.66 (1.20–2.22) | 1.62 (1.07–2.39) | 0.643 | 1.65 (1.18–2.04) | 1.46 (1.27–1.96) | 0.211 | 0.601 |
| Plasma-8-isoprostane, pg ml−1 | 17.4 (13.1–20.1) | 18.2 (13.4–21.0) | 0.678 | 16.5 (12.9–19.9) | 16.9 (14.7–19.6) | 0.210 | 1.00 |
| Urine- 8-isoprostane, pg nmol creatinine −1 | 86.4 (69.3–112.0) | 78.8 (63.6–90.8) | 0.134 | 83.4 (66.4–109.0) | 73.0 (61.4–85.0) | 0.003 | 0.832 |
Data presented as medians (interquartile ranges) and significant P values presented in bold
*p value calculated for changes within trials (pre vs post)
†p value calculated for changes between trials (change with HME vs change without HME)